Lenvanamo 4mg Capsule

About

Lenvatinib is an oral multi-kinase inhibitor indicated for the treatment of various advanced cancers. It exerts its antineoplastic activity by selectively inhibiting the kinase activities of vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET proto-oncogene. These receptors are crucial for tumor angiogenesis, tumor growth, and progression.

By targeting these pathways, lenvatinib helps to inhibit the formation of new blood vessels that feed tumors, thereby starving them and slowing their growth. Its broad spectrum of kinase inhibition makes it a valuable therapeutic option in malignancies that are often resistant to other treatments, offering improved outcomes for patients with advanced or metastatic disease.

Uses

• Treatment of differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine.
• First-line treatment for unresectable hepatocellular carcinoma (HCC).
• Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus.
• Treatment of advanced endometrial carcinoma in combination with pembrolizumab.

Directions For Use

Take this medication orally once daily, with or without food, as directed by your healthcare provider. Swallow the capsules whole; do not open or crush them.

Benefits

• Targets multiple key pathways involved in cancer growth and angiogenesis.
• Effective in treating several types of advanced and metastatic cancers.
• Offers an oral administration route, enhancing patient convenience.
• Can significantly improve progression-free survival in eligible patients.
• Provides a crucial treatment option for patients with limited therapeutic alternatives.
• May lead to tumor shrinkage and stabilization of disease progression.

Side Effects

• High blood pressure (hypertension)
• Fatigue and weakness
• Diarrhea
• Decreased appetite
• Nausea and vomiting
• Weight loss
• Protein in the urine (proteinuria)
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Underactive thyroid (hypothyroidism)
• Headache
• Abdominal pain
• Muscle and joint pain

Safety Measures

• Alcohol - It is generally advisable to limit or avoid alcohol consumption while on lenvatinib, as it may exacerbate side effects or place additional strain on the liver. Consult your doctor.
• Pregnancy - Lenvatinib is contraindicated during pregnancy due to potential fetal harm. Women of childbearing potential must use effective contraception during treatment and for at least one month after the last dose.
• Breastfeeding - Breastfeeding is not recommended during lenvatinib treatment and for at least one month after the last dose, as it is unknown if the drug is excreted in human milk and could cause serious adverse reactions in infants.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary for severe liver dysfunction. Regular monitoring of liver function tests is crucial during treatment.
• Kidney - Exercise caution in patients with renal impairment. Dose adjustments may be required for severe kidney dysfunction. Monitor kidney function regularly throughout therapy.
• Lung - Rare but serious pulmonary adverse events, including pneumonitis, have been reported. Patients should be monitored for new or worsening respiratory symptoms, and treatment may need to be interrupted or discontinued.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.